News coverage about Puma Biotechnology (NASDAQ:PBYI) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Puma Biotechnology earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.1034874244322 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Puma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback … – StreetInsider.com (streetinsider.com)
- Puma Biotechnology Inc (PBYI) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Puma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback from CHMP’s SAG (streetinsider.com)
- Biotech Updates: Aradigm Corporation & Puma Biotechnology (finance.yahoo.com)
- How Should You Think About Puma Biotechnology Inc’s (NASDAQ:PBYI) Risks? (finance.yahoo.com)
Several equities research analysts have issued reports on PBYI shares. Bank of America restated a “buy” rating and issued a $135.00 price target (up from $117.00) on shares of Puma Biotechnology in a report on Monday, October 9th. Citigroup restated a “buy” rating and issued a $156.00 price target (up from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. JPMorgan Chase & Co. restated a “buy” rating and issued a $131.00 price target on shares of Puma Biotechnology in a report on Wednesday, October 4th. Barclays reaffirmed a “buy” rating and set a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Finally, Stifel Nicolaus upped their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $130.67.
Puma Biotechnology (NASDAQ PBYI) opened at $99.25 on Friday. The firm has a market capitalization of $3,591.58, a PE ratio of -12.13 and a beta of 0.72. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the prior year, the company earned ($1.11) earnings per share. equities research analysts predict that Puma Biotechnology will post -8.17 EPS for the current fiscal year.
In related news, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 21.10% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.